Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies …
GSK abandons diversity targets following Trump pressure
Feb 27, 2025 · British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. …
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
6 days ago · GSK is fronting £38.5 million (nearly $50 million), in a partnership with South Korea’s ABL Bio to develop novel drugs for neurodegenerative diseases.. Aside from its upfront …
Next stage in GSK’s Zantac defense gets underway today
4 days ago · GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused …
GSK pens $2.5B pact for ABL's blood-brain barrier-bypassing tech
6 days ago · GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain …
GSK Chief Reaffirms Diversity Commitment Amid US Policy Changes
2 days ago · GSK plc is a global biopharma company. The Companyâ s segments include Commercial Operations and Research and Development. It develops cancer medicines for …
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced its largest U.S. manufacturing investment to date. The up to $800 million investment will bring state-of-the-art drug substance …
Press releases | GSK US
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation …
GSK targets neurodegenerative diseases with latest licensing deal
Apr 7, 2025 · GSK is betting potentially billions of dollars that a smaller drug company’s technology can help create new treatments for brain-corroding diseases. Through a licensing …
GSK makes fresh neuroscience foray with £2bn+ ABL deal
6 days ago · GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious diseases, including HIV, but the ABL deal and …